CG
PTGX icon

Cutler Group’s Protagonist Therapeutics PTGX Stock Holding History

Cutler Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-784
Closed -$18K – 5514
2022
Q1 		$18K Buy
784
+200
+34% +$5.63K ﹤0.01% 3154
2021
Q4 		$19K Buy
584
+484
+484% +$15.3K ﹤0.01% 3174
2021
Q3 		$1K Buy
+100
New +$4.26K ﹤0.01% 5392

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's PTGX Position: Q2 2022 in Review

Cutler Group sold out of Protagonist Therapeutics (PTGX) in Q2 2022, closing a stake of 784 shares — an estimated $18K sold.

Cutler Group first reported a position in PTGX in Q3 2021 and held it in 3 quarters. The position peaked at $19K in Q4 2021. 130 funds tracked by Wall St. Rank hold PTGX as of Q2 2022.

  • Cutler Group reported no remaining Protagonist Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cutler Group sold 784 Protagonist Therapeutics shares in Q2 2022, an estimated $18K.
  • Cutler Group first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 3 quarters.
  • Cutler Group's Protagonist Therapeutics position peaked at $19K in Q4 2021.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.